相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in Humans
Gill Holdsworth et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2021)
Area-based socioeconomic status and mortality: the Ludwigshafen Risk and Cardiovascular Health study
Angela P. Moissl et al.
CLINICAL RESEARCH IN CARDIOLOGY (2020)
Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women
Ian R. Reid et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Diabetes in the UK: 2019
C. A. Whicher et al.
DIABETIC MEDICINE (2020)
The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update
Tatiane Vilaca et al.
BONE (2020)
Correlation without a cause: an epidemiological odyssey
George Davey Smith et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)
Sclerostin and Vascular Pathophysiology
Antonino Catalano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes
Alessandra Piccoli et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2020)
Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics
Jonas Bovijn et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Sclerostin and its significance for children and adolescents with type 1 diabetes mellitus (T1D)
Anna Wedrychowicz et al.
BONE (2019)
Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates A Meta-analysis
Steven R. Cummings et al.
JAMA INTERNAL MEDICINE (2019)
Use of Mendelian Randomization to Examine Causal Inference in Osteoporosis
Jie Zheng et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Relationship between serum sclerostin, vascular sclerostin expression and vascular calcification assessed by different methods in ESRD patients eligible for renal transplantation: a cross-sectional study
Min Li et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2019)
Type 1 Diabetes and Bone Fragility: Links and Risks
Jakob Starup-Linde et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments
Matthew T. Drake et al.
BONE (2018)
Elevated levels of serum sclerostin are linked to adverse cardiovascular outcomes in peritoneal dialysis patients
Li Gong et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY (2018)
A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis
E. Michael Lewiecki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
Circulating levels of sclerostin are associated with cardiovascular mortality
Cristina Novo-Rodriguez et al.
PLOS ONE (2018)
Mechanisms of diabetes mellitus-induced bone fragility
Nicola Napoli et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Sclerostin's role in bone's adaptive response to mechanical loading
Gabriel L. Galea et al.
BONE (2017)
From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD
Vincent M. Brandenburg et al.
PEDIATRIC NEPHROLOGY (2016)
Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes
James J. Chamberlain et al.
ANNALS OF INTERNAL MEDICINE (2016)
Bone Mineral Density Is Positively Related to Carotid Intima-Media Thickness: Findings From a Population-Based Study in Adolescents and Premenopausal Women
Monika Frysz et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2016)
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
F. Cosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Type 2 diabetes and the skeleton: new insights into sweet bones
Vikram V. Shanbhogue et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
High Serum Sclerostin Levels Are Associated with a Better Outcome in Haemodialysis Patients
Guillaume Jean et al.
NEPHRON (2016)
Association of circulating sclerostin with vascular calcification in Afro-Caribbean men
Allison L. Kuipers et al.
ATHEROSCLEROSIS (2015)
LRP5 Regulates Human Body Fat Distribution by Modulating Adipose Progenitor Biology in a Dose- and Depot-Specific Fashion
Nellie Y. Loh et al.
CELL METABOLISM (2015)
The Impact of Diabetes and Diabetes Medications on Bone Health
Matthew P. Gilbert et al.
ENDOCRINE REVIEWS (2015)
High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study
Christiane Drechsler et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Osteocalcin as a hormone regulating glucose metabolism
Ippei Kanazawa
WORLD JOURNAL OF DIABETES (2015)
Osteocalcin Promotes β-Cell Proliferation During Development and Adulthood Through Gprc6a
Jianwen Wei et al.
DIABETES (2014)
The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus
Agostino Gaudio et al.
DIABETES & VASCULAR DISEASE RESEARCH (2014)
Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients
Mehmet Kanbay et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Renal Elimination of Sclerostin Increases With Declining Kidney Function
Daniel Cejka et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort
Abigail Fraser et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)
Cohort Profile: The 'Children of the 90s'-the index offspring of the Avon Longitudinal Study of Parents and Children
Andy Boyd et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2013)
2013 ESH/ESC Guidelines for themanagement of arterial hypertension The Task Force for the management ofarterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC)
Giuseppe Mancia et al.
JOURNAL OF HYPERTENSION (2013)
Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy
Yves Sabbagh et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2012)
Sclerostin Levels Associated with Inhibition of the Wnt/β-Catenin Signaling and Reduced Bone Turnover in Type 2 Diabetes Mellitus
Agostino Gaudio et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Roland Baron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Luigi Gennari et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
Association of Circulating Sclerostin Levels with Fat Mass and Metabolic Disease-Related Markers in Japanese Postmenopausal Women
Tomohiko Urano et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
The Appearance and Modulation of Osteocyte Marker Expression during Calcification of Vascular Smooth Muscle Cells
Dongxing Zhu et al.
PLOS ONE (2011)
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Asiri R. Wijenayaka et al.
PLOS ONE (2011)
A New Equation to Estimate Glomerular Filtration Rate
Andrew S. Levey et al.
ANNALS OF INTERNAL MEDICINE (2009)
The age/rage axis in diabetes-accelerated atherosclerosis
Karin Jandeleit-Dahm et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2008)
Endocrine regulation of energy metabolism by the skeleton
Na Kyung Lee et al.
CELL (2007)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
分享论文
